Addition Therapeutics (Series A)
Funding Details
Awarder
Inbox
Date Award
December 17, 2025
Vertical
Biotechnology
Funding Amount
$100,000,000
Company Info
Founders
Ron Park
Market
Genomic medicine for chronic and rare diseases
Location
South San Francisco, CA, USA
Coinvestors
Abingworth, BEVC, Gates Foundation, Osage University Partners, Pivotal Life Sciences, SR One
Company Description

Addition Therapeutics is on a mission to fulfill the transformative promise of genomic medicine for people impacted by both chronic and rare diseases. Leveraging our breakthrough all-RNA, non-viral, LNP-based PRINT™ platform, we are overcoming the limitations of existing genetic medicine modalities to develop safer, durable, one-time therapies.

Links